Goldman Sachs Group Inc.’s stock reversed course and rose Wednesday after the bank signaled better times ahead for deal making, despite second-quarter earnings that fell short of Wall Street’s lowered ...

IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for approval regardless. The company said that the study "narrowly missed" the ...

I am the editorial director, international, for Forbes Advisor. I have been writing about all aspects of household finance for over 30 years, aiming to provide information that will help readers make ...